Antibacterial effect of synthetic ultra-short lipopeptide on Streptococcus agalactiae and its active on bacterial mastitis in mice
Related Experiment Video
Updated: Oct 1, 2025
Intraductal Injection of LPS as a Mouse Model of Mastitis: Signaling Visualized via an NF-κB Reporter Transgenic
Published on: September 4, 2012
Jie Peng1, Qiangsheng Lu1, Xuming Liu1
1College of Veterinary Medicine, Gansu Agricultural University, Gansu, PR China.
Abstract:
Streptococcus agalactiae mastitis is one of the significant threats to the milk industry. The traditional antibiotic treatment method is easy to cause the emergence of resistant strains, and the problem of drug residue is increasingly severe. In this study, we designed and synthesized five lipopeptides. The antibacterial activity of different molecular structure lipopeptides against Streptococcus agalactiae was detected. Furthermore, the mouse mastitis model was established using Streptococcus agalactiae. The lipopeptides with better antibacterial effect were selected for the treatment experiment to evaluate the application value in the treatment of mastitis. The results showed that 4 of the synthesized lipopeptides had specific antibacterial activity. SLP3 and SLP4 have an excellent antibacterial effect and can treat murine mastitis caused by Streptococcus agalactiae infection within the safe concentration range. The results of this study can provide an excellent experimental basis for new antibiotics and clinical application in the treatment of dairy cow mastitis.
Insights
New lipopeptides show promise for treating Streptococcus agalactiae mastitis in dairy cows, offering an alternative to traditional antibiotics. SLP3 and SLP4 effectively treated mastitis in mice, indicating potential for reducing antibiotic resistance and residues.
Area of Science:
- Veterinary Medicine
- Microbiology
- Drug Discovery
Background:
- Streptococcus agalactiae causes significant economic losses in the dairy industry due to mastitis.
- Traditional antibiotic treatments for mastitis lead to antibiotic resistance and drug residues.
Purpose of the Study:
- To design and synthesize novel lipopeptides as potential therapeutic agents against Streptococcus agalactiae.
- To evaluate the in vitro antibacterial activity and in vivo efficacy of synthesized lipopeptides in a mouse mastitis model.
Main Methods:
- Synthesis of five novel lipopeptide structures.
- In vitro assessment of antibacterial activity against Streptococcus agalactiae.
- Establishment and treatment of a murine mastitis model using Streptococcus agalactiae.
Main Results:
- Four synthesized lipopeptides demonstrated specific antibacterial activity against Streptococcus agalactiae.
- Lipopeptides SLP3 and SLP4 exhibited excellent antibacterial effects.
- SLP3 and SLP4 effectively treated Streptococcus agalactiae-induced murine mastitis within a safe concentration range.
Conclusions:
- Lipopeptides SLP3 and SLP4 represent promising candidates for novel mastitis treatments in dairy cows.
- These findings support the development of new antibiotics to combat Streptococcus agalactiae mastitis, addressing concerns of resistance and residues.
